local_hospital

Medical Center Academica 2008 EOOD

Address
Ulitsa Todor Kableshkov 2, 5809 Pleven, Bulgaria

Medical Center Academica 2008 EOOD

Medical Center Academica 2008 EOOD is a specialized clinical research facility conducting advanced pharmaceutical trials across multiple therapeutic areas. The center demonstrates expertise in evaluating novel treatments for complex neurological and metabolic disorders, with a focus on improving patient outcomes through evidence-based medicine.

  • Chronic pain management associated with diabetic peripheral neuropathy
  • Relapsing forms of multiple sclerosis and immunomodulatory therapies
  • Pharmacokinetic and pharmacodynamic evaluation of innovative drug delivery systems

The research center specializes in comprehensive clinical assessments that examine both efficacy and safety profiles of investigational medications. With particular emphasis on neurological conditions, the facility conducts detailed studies evaluating subcutaneous and intravenous administration routes, radiological monitoring, and clinical outcomes. Their work in diabetic complications and autoimmune neurological disorders positions them as a key contributor to advancing treatment options for patients with chronic and debilitating conditions.

Site Overview

assignment
7
connected trials
corporate_fare
7
sponsors
science
7
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
3
Trials started 6–12 months ago
7
Total trials linked
Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
4
Sponsors (total)
7
Active sponsors
4

Sponsor Network

Top 4 by active trials.

lock +3 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 476 other sites in Bulgaria

description
Trial volume
7
Outperforms 64% of sites
public
Therapeutic diversity
2areas
Outperforms 47% of sites
groups
Sponsor diversity
7sponsors
Outperforms 72% of sites

Therapeutic Area Benchmark — Bulgaria

Select a therapeutic area to compare against other sites in Bulgaria.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Bulgaria

Market Share

Country: Bulgaria

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Medical Center Academica 2008 EOOD

lock Showing 1 of 7 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants with Parkinson’s Disease and ApathyIntegrative Research Laboratories Sweden ABPhase IRecruitingJan 2026

IMP list

lock Showing 1 of 7 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Botulinum Toxin Type A - Haemagglutinin Complex1Unknown2021-04-292021-04-29

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.